Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates
- 1 September 2008
- journal article
- review article
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 6 (3) , 89-94
Abstract
Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue resulting in compromised bone strength and an increased risk of fracture. There are two major fracture types: vertebral and nonvertebral. The latter include fractures involving the upper extremities, lower extremities (including hip), pelvis, and ribs. A recent review comparing the efficacy and safety of drugs approved by the US Food and Drug Administration for treatment of osteoporosis demonstrated that although all of the agents have been shown to reduce the incidence of radiographic vertebral fractures, they do not all reduce the incidence of nonvertebral fractures. This article summarizes the most currently available data relative to nonvertebral and hip fracture risk reduction for the N-containing bisphosphonates alendronate, ibandronate, risedronate, and zoledronic acid, and presents results of an analysis of comparative efficacy of these compounds using the technique of adjusted indirect comparisons.Keywords
This publication has 38 references indexed in Scilit:
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database of Systematic Reviews, 2008
- Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial dataCurrent Medical Research and Opinion, 2007
- Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION studyCurrent Medical Research and Opinion, 2007
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trialsInternational Journal Of Clinical Practice, 2006
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnnals of the Rheumatic Diseases, 2006
- Anti-Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical TrialsJournal of Bone and Mineral Research, 2006
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisBone, 2004